Ceritinib-d7

Names

[ Name ]:
Ceritinib-d7

Biological Activity

[Description]:

Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

[Related Catalog]:

Research Areas >> Cancer

Research Areas >> Endocrinology

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> ALK

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> IGF-1R

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Insulin Receptor

[References]

[1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₈H₂₉D₇ClN₅O₃S

[ Molecular Weight ]:
565.18

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.